About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/healthcare-professionals
Refer a Patient to MSKCC:
mskcc.org/refer
COVID-19
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
Events
MPN
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Y
ESMO 2021 Update on Nivo + Chemo or Ipi vs. Chemo as 1L Treatment in Advanced GC/GEJC/EAC: CheckMate 649 Study
By
Memorial Sloan Kettering Cancer Center
FEATURING
Yelena Y. Janjigian
By
Memorial Sloan Kettering Cancer Center
FEATURING
Yelena Y. Janjigian
205 views
October 11, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Gastrointestinal
04:39
Insights from 2024 ASCO® GI Annual Meeting
ASCO® GI 2024 Insights: "PROOF 301 Trial - Oral FGFR Inhibitor …
Feat.
G. Abou-Alfa
06:31
ecancer
CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for P…
Feat.
Y. Y. Janjigian
31:25
Total Health
Updates in Rectal Cancer: Optimizing Response, Preserving the Organ,…
Feat.
J. Smith
10:36
CE Concepts
Pathophysiologic Foundations in HCC/BTC: Immune System as a Therapeu…
Feat.
J. Harding
11:02
ASCO GI 2023 Conference Coverage
ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. C…
Feat.
Y. Y. Janjigian
07:43
ASCO GI 2023 Conference Coverage
ASCO GI 2023 ctDNA for Response Assessment in Patients With Anal Can…
Feat.
J. Alvarez
06:16
ASCO GI 2023 Conference Coverage
ASCO GI 2023 on Organ Preservation and Total Neoadjuvant Therapy for…
Feat.
P. Romesser
38:04
Debbie's Dream Foundation
Advances in IO and Targeted Agents in Gastroesophageal Cancer
Feat.
D. Ilson
05:41
ecancer
An Overview of Treatment Advances in Gastric Cancer
Feat.
D. Ilson
04:07
ecancer
ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment i…
Feat.
A. Cercek
09:42
ASCO 2022 Conference Coverage
ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Ca…
Feat.
J. Harding
58
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advance…
Feat.
J. Harding
06:42
ASCO 2022 Conference Coverage
ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabin…
Feat.
G. Abou-Alfa
23
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine …
Feat.
G. Abou-Alfa
07:48
ecancer
Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMAL…
Feat.
G. Abou-Alfa
20:26
Collaborative Group of the Americas for Inherited Gastrointestinal Cancers
Incidental Findings From Somatic Testing and Implications for Heredi…
Feat.
Z. Stadler
08:15
ASCO GI 2022 Conference Coverage
ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…
Feat.
R. Sugarman
05:49
ASCO GI 2022 Conference Coverage
ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Stu…
Feat.
Y. Y. Janjigian
09:30
Memorial Sloan Kettering Cancer Center
ESMO 2021 Update on Nivo + Chemo or Ipi vs. Chemo as 1L Treatment in…
Feat.
Y. Y. Janjigian
07:44
Memorial Sloan Kettering Cancer Center
ESMO 2021 Abstract Review on Genomic Landscape of Late-Stage Gastric…
Feat.
Y. Y. Janjigian
16:43
Debbie's Dream Foundation
Gastric Cancer: Advances in Systemic Therapy
Feat.
D. Ilson
07:10
2021 ASCO Virtual Direct™ Highlights
2021 ASCO CRC Updates: 1L Pembro vs. Chemo, Maintenance Chemo, 2L an…
Feat.
L. Connell
09:50
Memorial Sloan Kettering Cancer Center
1L Treatment Updates for Advanced GE/GEJ Cancers: OS Data for Nivo+I…
Feat.
Y. Janjigian
21:21
Memorial Sloan Kettering Cancer Center
Frontline Management of Advanced GEJ Cancers: Will 5FU/Oxaliplatin +…
Feat.
Y. Y. Janjigian
11:00
Memorial Sloan Kettering Cancer Center
BRAF Alterations in Advanced CRC: How Common Are V600E Mutations? Ho…
Feat.
R. Yaeger
17:05
Memorial Sloan Kettering Cancer Center
Liver-Directed Therapy for mCRC: What Is the Goal, When to Use and H…
Feat.
A. Cercek
13:27
2020 Virtual ESMO Review
2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoi…
Feat.
L. Connell
08:07
2020 Virtual ESMO Review
2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the Qoli…
Feat.
L. Connell
11:33
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxa…
Feat.
L. Connell
09:21
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New So…
Feat.
L. Connell
14:43
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafen…
Feat.
L. Connell
22:02
Memorial Sloan Kettering Cancer Center
The Role of Modern RT Techniques in Management of Esophagogastric Ca…
Feat.
A. Wu
18:32
Memorial Sloan Kettering Cancer Center
Advanced Surgical Techniques for Early Stage Esophagogastric Cancer:…
Feat.
D. Molena
20:17
Memorial Sloan Kettering Cancer Center
Current and Future Personalized Systemic Targets in Esophagogastric …
Feat.
G. Ku
